Tools I Use

Real-Time Market Scanner

Fast movers • Alerts • Momentum
10% OFF with SAVE10

Start Free

Finviz Elite stock screener charts heatmaps insiders and filters

Recommended Platform

Professional Trading Workflow

Charts • Watchlists • Multi-broker tools
Built for active traders

Visit Medved Trader

Merlintrader Trading Pub

Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub

Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Europe

Premarket Update (Inizio Settimana) – Tech, Futures in Rialzo Moderato e Focus Biotech Catalyst | Merlintrader trading Blog

Premarket update Start of week Date: December 22, 2025

Positive futures, tech strength and a biotech catalyst focus from the calendar

Christmas week: lower liquidity, often faster and more technical moves. Below: market movers, Europe/commodities, and a biotech section built on calendar catalysts (RVPH, ARGX, AARD, plus notes on ZLAB and HALO).

Sentiment: constructive Sentiment: neutral / watch Sentiment: high volatility / elevated risk

Markets – Premarket

Nasdaq 100 Futures Up modestly

Follow-through tone; risk-on led by AI/Chip names.

S&P 500 Futures Up modestly

Modestly higher open expected; watch for false breakouts in low liquidity.

Dow Jones Futures Slightly higher

More muted participation vs tech; market remains selective.

Weekly setup Low volumes

More weight on company news and catalysts; technical moves can be amplified.

Market movers – AI, chips and mega-caps

Name	Premarket	Context / idea
Nvidia (NVDA)	Higher	AI theme still strong; watch reactions to ecosystem/partnership headlines.
Micron (MU)	Higher	Strength after last week’s results; momentum across memory/AI supply chain.
Oracle (ORCL)	Higher	Still riding infrastructure-related headlines; remains news-driven.
Tesla (TSLA)	Higher	Premarket strength; expect elevated intraday volatility.

Europe, commodities and FX

Item	Level	Note
FTSE MIB (Italy)	Cautious	Typical pre-holiday tone; volumes often thin.
DAX (Germany)	Slightly higher	Supported by semis; Infineon in focus.
Gold	At records	Trading above $4,400/oz; perceived hedge and risk-off ballast.
WTI	Around mid-$50s	Useful risk-on gauge; impacts energy sentiment.
Bitcoin	Above $88k	Risk-on tone remains, but volatility is structurally high.
EUR/USD	Stable	Relevant for cross-asset positioning and risk appetite.

Events to watch

No major macro prints today. Tomorrow (Dec 23): BEA GDP release (Q3) and Durable Goods Orders. US markets: early close on Dec 24 at 1:00 PM ET; closed on Dec 25.

Biotech Special – Calendar catalysts

While big tech leads volume and attention, speculative focus can shift toward healthcare catalysts. In low-liquidity weeks, reactions to clinical data and press releases can be faster and amplified.

RVPH – Reviva Pharmaceuticals

High volatility expected Regulatory timing: Q2 2026 target (conditional)

From the calendar: Phase 3 schizophrenia program around brilaroxazine. Company communications have highlighted the 12-month Open-Label Extension (RECOVER OLE) dataset with sustained efficacy and a generally favorable safety profile. Weight change has been described as mild and quantified at approximately +1.52 kg pooled at one year (and around +1.28 kg at 50 mg).

Regulatory note: management has guided to an FDA meeting in Q4 2025 and a potential NDA submission targeted for Q2 2026, subject to FDA feedback.

ARGX – argenx

Large-cap stability Constructive 2026 outlook

From the calendar: conference presentations and clinical updates. Recent UplighTED program communications in thyroid eye disease and the “Vision 2030” strategic framing remain supportive. 2026 drivers include continued Vyvgart indication expansion.

AARD – Aardvark Therapeutics

Metabolic / appetite disorders Calendar watch

Aardvark’s focus is metabolic and hunger-related disorders (including its HERO Phase 3 program in Prader-Willi Syndrome). Calendar attention is on clinical/regulatory execution rather than dermatology.

Dermatology note – Prurigo Nodularis

Prurigo Nodularis remains a competitive dermatology area, following positive readouts and updates from Galderma (Nemluvio) and Incyte (ruxolitinib cream). Any new comparable data in this space can move names quickly in thin holiday liquidity.

Technical notes – other calendar names

Zai Lab (ZLAB): relative strength
Improving tone supported by expansion in China of oncology therapies; watch for company updates and sector flow.

Halozyme (HALO): royalties / cash-flow profile
Often sensitive to partner regulatory events involving ENHANZE. Monitor partner press releases during typical US premarket timing.

Ideas for the week

Low volumes: higher odds of amplified technical moves and false breakouts.
In biotech, clinical catalysts can outweigh macro into year-end.
Large-cap (ARGX) as sector anchor; small-cap names as volatility engine and news-driven optionality.
Watch premarket press releases: holiday weeks can concentrate updates in less crowded windows.

Biotech Catalyst Calendar

Full biotech catalyst calendar (PDUFA, clinical readouts, regulatory meetings) updated on the site.

Open the calendar

Premarket update Inizio settimana Data: 22 dicembre 2025

Futures in rialzo moderato, tech in spinta e focus biotech sui catalyst del calendario

Settimana di Natale: volumi in calo e movimenti spesso più tecnici. Qui sotto trovi market movers, quadro Europa/commodities, e un blocco “Speciale Biotech” costruito sui catalyst del calendario (RVPH, ARGX, AARD, più note su ZLAB e HALO).

Sentiment: costruttivo Sentiment: neutro / da monitorare Sentiment: alta volatilità / rischio elevato

Quadro mercati – Premarket

Nasdaq 100 Futures In rialzo moderato

Tono risk-on guidato da AI/Chip; attenzione a movimenti tecnici amplificati.

S&P 500 Futures In rialzo moderato

Apertura attesa positiva; possibili false rotture in bassa liquidità.

Dow Jones Futures Leggermente positivo

Partecipazione più contenuta rispetto al tech; mercato selettivo.

Setup settimana volumi ridotti

Più peso a news societarie e catalyst; movimenti tecnici amplificati.

Market movers – AI, chip e mega-cap

Titolo	Premarket	Contesto / idea
Nvidia (NVDA)	In rialzo	Sentiment AI ancora positivo; attenzione a headline su ecosistema e partnership.
Micron (MU)	In rialzo	Forza dopo i risultati della scorsa settimana; momentum su supply chain AI/memoria.
Oracle (ORCL)	In rialzo	Titolo ancora “news-driven”; riflette headline su infrastruttura e grandi clienti.
Tesla (TSLA)	In rialzo	Forza in premarket; volatilità intraday tipicamente elevata.

Europa, commodities e valute

Voce	Livello	Nota
FTSE MIB (Milano)	Cauto	Settimana pre-festiva: volumi ridotti e volatilità spesso “a scatti”.
DAX (Germania)	Leggermente positivo	Sostegno dal settore semiconduttori; Infineon tra i nomi in evidenza.
Oro	Su record	Livelli oltre 4.400 $/oncia; bene rifugio e copertura percepita.
WTI	Area metà 50$	Termometro risk-on e driver per energy sentiment.
Bitcoin	Sopra 88.000 $	Contesto risk-on, ma volatilità strutturalmente alta.
EUR/USD	Stabile	Rilevante per positioning e lettura risk appetite cross-asset.

Eventi da monitorare

Oggi nessun macro di grande rilievo. Domani (23 dicembre): rilascio BEA sul PIL USA (Q3) e dati su ordini di beni durevoli. Mercati USA: chiusura anticipata il 24 dicembre alle 13:00 ET, chiusi il 25 dicembre.

Speciale Biotech – Catalyst dal calendario

Mentre i big tech guidano volumi e attenzione, il focus speculativo può spostarsi sui catalyst sanitari. In settimane a bassa liquidità, le reazioni a dati clinici e comunicati possono essere più rapide e amplificate.

RVPH – Reviva Pharmaceuticals

Alta volatilità attesa Timing regolatorio: target Q2 2026 (condizionato)

Dal calendario: programma Fase 3 su brilaroxazine (schizofrenia). Le comunicazioni societarie hanno evidenziato il dataset a 12 mesi dell’Open-Label Extension (RECOVER OLE), con efficacia sostenuta e profilo di sicurezza generalmente favorevole. La variazione di peso è stata descritta come “mild” e quantificata in circa +1,52 kg nel pooled a 1 anno (e circa +1,28 kg al dosaggio 50 mg).

Nota regolatoria: management ha indicato un meeting con FDA in Q4 2025 e una possibile NDA mirata al Q2 2026, subordinata al feedback dell’agenzia.

ARGX – argenx

Solidità large-cap Outlook 2026 costruttivo

Dal calendario: presentazioni e aggiornamenti clinici. Le comunicazioni sul programma UplighTED (thyroid eye disease) e la cornice strategica “Vision 2030” restano elementi di supporto; nel 2026 il driver chiave è l’espansione delle indicazioni di Vyvgart.

AARD – Aardvark Therapeutics

Focus metabolico / appetito Catalyst da calendario

Aardvark è focalizzata su disturbi metabolici e della regolazione dell’appetito (incluso il programma HERO in Fase 3 nella sindrome di Prader-Willi). L’attenzione da calendario riguarda l’esecuzione clinica/regolatoria, non la dermatologia.

Nota dermatologia – Prurigo Nodularis

La Prurigo Nodularis resta un’area dermatologica molto competitiva, dopo update e dati positivi di Galderma (Nemluvio) e Incyte (ruxolitinib cream). In bassa liquidità, nuove evidenze comparabili possono muovere rapidamente i titoli esposti al tema.

Nota tecnica – altri titoli del calendario

Zai Lab (ZLAB): forza relativa
Tono in miglioramento legato all’espansione in Cina di terapie oncologiche; attenzione a comunicati e flussi settoriali.

Halozyme (HALO): royalty / cash-flow
Spesso sensibile a scadenze regolatorie dei partner che usano ENHANZE. Monitorare comunicati dei partner nelle finestre tipiche premarket USA.

Idee per la settimana

Volumi ridotti: più probabilità di movimenti tecnici amplificati e rotture “false”.
In biotech, spesso i catalyst clinici pesano più del macro fino a fine anno.
Large-cap (ARGX) come “ancora” di settore; small-cap come motore di volatilità e movimenti news-driven.
Attenzione ai comunicati premarket: in settimane festive alcuni update escono in finestre meno affollate.

Biotech Catalyst Calendar

Calendario completo dei catalyst biotech (PDUFA, readout clinici, meeting regolatori) aggiornato sul sito.

Apri il calendario

✦ Disclaimer: The information provided is strictly for educational and informational purposes. This content represents independent, informational research and does not constitute regulated investment research or financial advice. I am not a licensed financial advisor or an authorized investment professional. Nothing here should be interpreted as a recommendation to buy, sell, or trade any security. If you need personalized financial advice, you should consult a qualified and authorized professional. Biotech and small-cap stocks carry significant risk, including the potential loss of all invested capital. Each user remains fully responsible for their own trading decisions. Full legal disclaimers.

✦ RunUP Biotech: Interested in understanding market dynamics around FDA catalysts and clinical trials? The RunUP Biotech strategy provides a framework for analyzing pre-event positioning, volume patterns, and risk-management approaches. Educational focus on probability and pattern structure — not predictions or guaranteed outcomes. Learn more →

✦ Support Merlintrader: This website is free and has no paywall. If you find the reports and tools useful, you can support the project via Buy Me a Coffee — it helps me cover costs and keep publishing independent analysis.

Real-Time Market Scanner

Professional Trading Workflow

Positive futures, tech strength and a biotech catalyst focus from the calendar

Markets – Premarket

Market movers – AI, chips and mega-caps

Europe, commodities and FX

Events to watch

Biotech Catalyst Calendar

Futures in rialzo moderato, tech in spinta e focus biotech sui catalyst del calendario

Quadro mercati – Premarket

Market movers – AI, chip e mega-cap

Europa, commodities e valute

Eventi da monitorare

Biotech Catalyst Calendar

Try ChartsWatcher free, then unlock 10% OFF with SAVE10

One platform. All your brokers.

Tools and research platforms used by Merlintrader

AI usage disclosure

Author's note

Legal disclaimer – please read carefully

Biotech Catalyst Calendar